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HR’s “data” are marked Private and 
Conﬁ dential. Some things must be 
believed. To question them is heresy.
We hope to report back on our Head’s 
one-to-one interview with himself. 
After all, we have his word, and that 
of College senior management, that 
the restructuring is proceeding with 
complete fairness and transparency. 
Perhaps he’ll use a mirror?
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Queen Mary: nobody 
expects the Spanish 
Inquisition
Three timely Oﬄ  ine columns by 
Richard Horton1–3 describe a mindless 
managerial rampage spreading through 
Queen Mary University of London, UK. 
Barts and The London, Queen Mary’s 
School of Medicine and Dentistry, 
has declared distinguished medical 
researchers to be at risk of redundancy.1 
Queen Mary’s School of Biological and 
Chemical Sciences now follows suit.2,3 As 
we write, colleagues declared to be “at 
risk” just 2 weeks ago are summoned 
individually to closed audiences 
with the Head of School, attended 
by members of the ironically named 
“Human Resources” (HR) department. 
If targeted individuals fail to appease 
the inquisitor, they will be sacked. 
Other staﬀ  members are earmarked for 
demotion, with replacement “Teaching 
and Scholarship” contracts that will 
oblige them to desist from independent 
research.
But, one might ask, is it not 
high time to weed out slackers? It 
might help if one had any way of 
knowing who they are. Sadly, the 
“restructuring” hits exactly the wrong 
targets in many cases, and leaves 
unproductive academics unscathed. 
The reason is simple—the Head of 
School and HR have neither interest 
in, nor understanding of, individuals’ 
research, still less their research 
potential. This slaughter of the 
talented relies entirely on a carefully 
designed set of retrospective counts 
of the uncountable. These are labelled 
research “metrics”.
Are we here engaged in special 
pleading? Actually, no.4 Our school 
has a reputation, envied worldwide, 
for research by individuals now for 
the chop. Their retrospective crimes, 
committed between 2008 and 2011, 
include too few publications as a 
“signiﬁ cant” author in high-impact 
journals, and below-average external 
funding. Where the baseline of research 
income derived from the Higher 
Education Funding Council for England 
has disappeared, no-one seems to 
know. So, we are looking at the end of 
the road for unique and internationally 
leading-edge Queen Mary research. 
Among many outstanding projects 
we stand to lose are: sociogenomics 
of mole rats, the only eusocial 
mammals, and a model, incidentally, 
for the endocrinology of bullying; 
genetics of circadian rhythms and iron 
homoeostasis from experiments on 
fruit-ﬂ ies; imaging of neural activity in 
zebraﬁ sh—a paradigm for vertebrate 
development; and heterogeneous 
catalytic oxidation and carbon–
carbon coupling in inorganic chemical 
synthesis. The list is long. Alas, there 
are no boxes to tick for advances in 
knowledge and understanding—no 
metrics for science itself.
Over in the Medical and Dental 
School, the grand inquisitor is identiﬁ ed 
as the Dean for Research, whose own 
research credentials are, naturally, 
unavailable for scrutiny.1 Never mind, 
we now have the assurance from his 
colleague that “Each and every faculty 
member of the college was assessed in 
this process and from my own personal 
point of view it was done fairly...”5 
Who needs evidence in the face of 
such assurance? “Consequently, to pick 
him out for criticism in this disgraceful 
manner is quite iniquitous”.5 Yet the 
Dean managed to pick out others—for 
oblivion, not just criticism. And he got 
it wrong.1
The same double standard follows, 
now, in our School of Biological and 
Chemical Sciences. For example, one 
of the “metrics” for research output at 
professorial level is to have published 
at least two papers in journals with 
impact factors of 7 or more. This is 
ludicrous, of course—a triumph of 
vanity as sensible as selecting athletes 
on the basis of their brand of track suit. 
But let us follow this “metric” for a 
moment. How does the Head of School 
fair? Zero, actually. He fails. Just consult 
Web of Science. Take care though, 
the result is classiﬁ ed information. 
Catheter-directed 
thrombolysis for acute 
deep vein thrombosis
Tone Enden and colleagues’ random-
ised trial of catheter-directed throm-
bolysis (CDT) in patients with high 
proximal deep vein thrombosis 
(Jan 7, p 31)1 is well designed and the 
results have been eagerly awaited. 
However, we feel that caution is 
recommended in assigning the 14·4% 
absolute reduc tion in the risk of post-
thrombotic syndrome in patients on 
CDT to thrombolysis.
Besides additional treatment, CDT 
patients were more compliant with 
wearing compression stockings than 
were patients who did not receive 
CDT. Although the diﬀ erence in 
compliance of 11·8% is not signiﬁ cant, 
it is relevant. Daily use of compression 
stockings reduces the risk of post-
thrombotic syndrome by 50%.2,3 
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other indirect costs associated with 
the longer hospital stay necessary.
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the incidence of post-thrombotic 
syndrome in Enden and colleagues’ 
study, we calculate an expected 
absolute risk reduction in CDT patients 
of 4%, owing to better compliance 
with compression stocking use.
Furthermore, more CDT patients 
than non-CDT patients had good-
quality anticoagulant treat ment at 
both follow-up points. Oral anti-
coagulant treatment that achieves an 
international normalised ratio within 
the therapeutic range reduces the risk 
of post-thrombotic syndrome by 63% 
compared with patients who spend 
more than 50% of time beneath the 
therapeutic range.4 Unfortunately, 
time in therapeutic range was not 
reported in Enden and colleagues’ 
trial and was not accounted for in 
examining the eﬀ ect of CDT on post-
thrombotic syndrome.
The CDT strategy, with its more 
intense treatment and hospital 
admission, does seem to improve out-
come. However, this might not be 
the eﬀ ect of additional thrombolysis. 
Instead, it could be due to more intense 
initial patient support, which results 
in more awareness of the relevance of 
treatment compliance. We feel that 
taking treatment compliance into 
account is important before coming 
to conclusions about the eﬀ ect of 
thrombolysis on post-thrombotic 
syndrome and before exposing patients 
to costly and invasive procedures.
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Tone Enden and colleagues, in their 
CaVenT trial,1 explore the interesting 
hypothesis of catheter-directed 
thrombolysis (CDT) in the prevention 
of post-thrombotic syn drome. We 
have several comments. 
In the Intro duction section, 
reference to the updated Cochrane 
review2 as sug gesting a beneﬁ t of 
systemic thrombolysis in prevention 
of post-thrombotic syndrome comes 
with the caveat that the only study 
with a Jadad score of greater than 3 
showed no beneﬁ t.3
The CaVenT trial was done in four 
specialised centres, and hence the 
outcomes might be very diﬀ erent 
elsewhere. Additionally there might 
have been a learning curve for 
optimum results with CDT; hence 
it would be interesting to have a 
comparison of those who entered the 
trial earlier versus those who entered 
later.
Enden and colleagues do not present 
the bleeding rates (if any) for the 
control group, and hence a number 
needed to harm is not available. Also, 
the rate of stent placement and its 
association with outcomes would have 
been interesting, especially in view of 
scant evidence available on the topic.4
The limitations of the open-label 
design might have manifested with 
an obvious greater adherence to oral 
anticoagulation in the CDT group at 
6 months. Finally, Enden and col-
leagues imply a cost eﬀ ectiveness with 
CDT, citing the cost associated with 
post-thrombotic syndrome;5 however, 
it would be interesting to assess the 
expense associated with CDT and 
Authors’ reply
Both sets of correspondents raise 
an issue about whether the noted 
absolute reduction in post-thrombotic 
syndrome of 14·4% in patients treated 
with additional catheter-directed 
thrombolysis (CDT) could be attri-
buted to the thrombolytic treatment 
alone, since a higher proportion of 
these patients reported daily wear of 
elastic com pression stockings and had 
international normal ised ratios within 
the therapeutic range.
We agree that the non-signiﬁ cant 
tendency to better compliance could 
be attributable to the inherent risk of 
bias of this open-label randomised 
controlled trial, and relevance to the 
noted eﬀ ect size cannot be ruled out. 
However, we think the eﬀ ect on post-
thrombotic syndrome cannot be 
simpliﬁ ed as suggested by Inge van 
Schouwenburg and colleagues. First, 
the two landmark studies on the use 
of elastic com pression stockings1,2 
reported on patients with any level of 
proximal deep vein thrombosis (DVT) 
from the popliteal vein and up, whereas 
our patients had a high proximal 
